UroGen Pharma Ltd. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
UroGen Pharma Ltd. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2017 to Q2 2024.
  • UroGen Pharma Ltd. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $3.56M, a 60.2% increase year-over-year.
  • UroGen Pharma Ltd. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $11.2M, a 19.7% increase year-over-year.
  • UroGen Pharma Ltd. annual Share-based Payment Arrangement, Expense for 2023 was $9.34M, a 11.7% decline from 2022.
  • UroGen Pharma Ltd. annual Share-based Payment Arrangement, Expense for 2022 was $10.6M, a 54.2% decline from 2021.
  • UroGen Pharma Ltd. annual Share-based Payment Arrangement, Expense for 2021 was $23.1M, a 17.5% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $11.2M $3.56M +$1.34M +60.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $9.81M $2.76M +$470K +20.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 $9.34M $2.61M +$243K +10.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $9.1M $2.22M -$216K -8.85% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $9.32M $2.22M -$601K -21.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $9.92M $2.29M -$663K -22.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 $10.6M $2.37M -$2.99M -55.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $13.6M $2.44M -$3.08M -55.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $16.6M $2.82M -$3.22M -53.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $19.9M $2.95M -$3.25M -52.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $23.1M $5.36M -$1.17M -17.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-24
Q3 2021 $24.3M $5.52M -$1.25M -18.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $25.5M $6.05M -$1.07M -15.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $26.6M $6.2M -$1.42M -18.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $28M $6.53M -$1.54M -19.1% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-21
Q3 2020 $29.6M $6.76M -$480K -6.63% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $30M $7.12M -$93K -1.29% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $30.1M $7.62M +$170K +2.28% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $30M $8.07M -$812K -9.15% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-18
Q3 2019 $30.8M $7.24M -$2.27M -23.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $33.1M $7.21M -$497K -6.45% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $33.5M $7.45M +$2.91M +64% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $30.6M $8.88M +$6.61M +291% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-02
Q3 2018 $24M $9.52M +$7.36M +341% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $16.7M $7.71M +$6.13M +389% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 $10.5M $4.54M +$4.24M +1429% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $6.3M $2.27M Oct 1, 2017 Dec 31, 2017 10-K 2020-03-02
Q3 2017 $2.16M Jul 1, 2017 Sep 30, 2017 6-K 2018-11-13
Q2 2017 $1.58M Apr 1, 2017 Jun 30, 2017 6-K 2018-08-14
Q1 2017 $297K Jan 1, 2017 Mar 31, 2017 6-K 2018-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.